Translational relevance
Fibroblast growth factor receptor 1 (FGFR1) is an attractive therapeutic target in various types of cancer. Multiple FGFR inhibitors are currently evaluated in clinical trials, including the potent and selective pan-FGFR inhibitor AZD4547. In this study, we identify frequent overexpression of FGFR1 protein in a large cohort of head and neck squamous cell carcinoma (HNSCC) patient samples.
Treatment of an FGFR1-overexpressing HNSCC cell line with AZD4547 reduces cell proliferation and FGFR signaling. Furthermore, we identify EGFR signaling as a resistance mechanism to FGFR inhibition, which can be circumvented by combined AZD4547 and gefitinib treatment. These findings provide a rationale to test combined AZD4547 and gefitinib treatment in clinical trials for FGFR1-overexpressing HNSCC.
Research. 
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) causes more than 293,000 cancer-related deaths annually worldwide and is characterized by frequent regional metastases and a poor survival rate of 65% (1, 2) . For advanced stage disease, current surgical and chemoradiotherapeutic treatment regimens are frequently ineffective and often cause severe side effects (3) . In addition, the use of targeted therapies for treating advanced HNSCC is limited to the epidermal growth factor receptor (EGFR) inhibitor cetuximab (4) . The high mortality rate of advanced HNSCC and varying therapeutic success highlight the need for novel therapeutic strategies.
Recently, large-scale genomic studies have identified potential molecular targets in HNSCC, including fibroblast growth factor receptor 1 (FGFR1) (5) (6) (7) . The FGFR1 gene is mutated or overexpressed in HNSCC and a wide spectrum of other solid tumors, including glioblastoma, melanoma, breast, lung, prostate, bladder, and ovarian cancer (7) (8) (9) (10) (11) (12) (13) (14) . These tumorigenic FGFR1 aberrations constitutively activate FGFR1 and downstream MAPK, PI3K/AKT, PLCγ, and JAK/STAT signaling pathways, thereby contributing to tumor development (15) . Therapies inhibiting FGFR1 have shown to reduce HNSCC development in preclinical models, and are currently being tested in clinical trials on solid tumors, including HNSCC (16-19) (NCT01962532, NCT01004224, and NCT01948297).
Several multi-kinase inhibitors targeting FGFR and other kinases, e.g. dovitinib and lucitanib, have already shown great therapeutic potential in clinical studies on FGFR-aberrated breast cancer and various other advanced solid tumors (20, 21) . A novel selective and potent pan-FGFR inhibitor AZD4547 is currently tested in phase 2 clinical trials on various types of cancer (ClinicalTrials.gov Identifier: NCT01795768, NCT01791985). However, resistance to FGFR-inhibitors and sequential therapy failure are likely to occur.
In this study we have investigated the prognostic and therapeutic value of FGFR1 in HNSCC and the potential of AZD4547 as a targeted therapy for HNSCC.
METHODS

Patient cohort
Inclusion criteria for the study population were: patients with a first primary HNSCC in the oral cavity or oropharynx who were treated at the University Medical Center Utrecht (UMC Utrecht) between August 1996 and December 2011. Exclusion criteria were: HNSCC in the nasopharynx, hypopharynx or larynx, a previous history of HNSCC, a synchronous primary tumor, histologic abnormalities including inflammation and dysplastic lesions, unknown HPV status, and the absence of tumor cores on tissue microarray (TMA) slides. The patient cohort included 452 HNSCC patients, of which 212 were oral squamous cell carcinoma (OSCC) and 240 were oropharyngeal squamous cell carcinoma (OPSCC).
Nine patients were excluded because HPV status was unknown and seven were excluded because TMA cores were absent for the tumor, leaving 436 patients for analysis of FGFR1 protein expression (Table 1) . This patient cohort was previously described (22, 23) .
HNSCC patients were treated according to the Dutch National Guideline for Head and Neck Cancer 2014 (Richtlijn Hoofd-hals tumoren, 2014). The treatment regimen for OSCC was primary surgical resection and an additional neck dissection and/or postoperative (chemo)radiotherapy if recommended by the multidisciplinary team. The treatment regimen for OPSCC was primary surgery or (chemo)radiotherapy with additional neck dissection or postoperative (chemo)radiotherapy if recommended. OSCC patients were primarily treated by surgery and the majority of OPSCC were treated by (chemo)radiotherapy. Median follow-up time for overall survival of HPV-positive HNSCC patients was 68 months and for disease-free survival 60.5 months. Median follow-up time for overall survival of HPV-negative HNSCC patients was 86 months and for disease-free survival 85 months.
Clinicopathological characteristics and follow-up data of these patients were retrieved from electronic medical records. Formalin-fixed paraffin-embedded (FFPE) tissues of all tumors were collected. OSCC tissues were primarily surgical resection specimens and OPSCC tissues were primarily pretreatment 
Tissue microarray construction
FFPE tissues were assembled into tissue microarrays using a TMA Grand Master instrument (3D HISTECH). A head and neck pathologist (SMW) marked the tumor areas of FFPE tissues on haematoxylin and eosin stained slides. Three cores (0.6mm) were punched from tumor areas of each FFPE tumor tissue and arrayed into a recipient paraffin block. Normal oral and tonsillar and placenta tissue were arrayed into the recipient paraffin block and served as quality control of staining (24) .
Immunohistochemistry
To determine FGFR1 protein expression in patient samples, slides (4µm) of TMA blocks were mechanically stained using a Ventana BenchMark Ultra automated staining instrument (Ventana tumors in the analysis had only two cores available, for which the mean percentage and maximum stain intensity was derived from two cores. 37 tumors had one core available, for which the percentage and stain intensity was scored from one core. Cutoff values for continuous percentages and stain intensities were optimized on predicting patient overall survival and disease-free survival using the log likelihood ratio. This method has been described as the best method for selecting cutoff values in previous studies (25) . A cutoff value of 10% was selected for FGFR1 protein expression because it best predicted patient overall survival and disease-free survival. Above 10% was defined as "overexpression" and below as "low expression". Other values for the percentage of positively stained tumor cells and stain intensity were much less discriminative in predicting overall survival and diseasefree survival and were not further used in this study (data not shown).
Fluorescence In Situ Hybridization (FISH)
To assess FGFR1 copy-numbers, TMA slides were hybridized with FGFR1 break apart/amplification FISH probes (Cytocell aquarius). In short, unstained TMA slides (4 μm) were deparaffinised and treated with citrate and protease. Next, slides were washed and dehydrated in preparation for hybridization. 15 µL FISH probe was applied and slides were hybridized at 37°C in a ThermoBrite instrument (Abbott Laboratories). Subsequently, slides were washed thoroughly with saline-sodium citrate buffers and counterstained with DAPI. Finally, slides were dehydrated and mounted with Vectashield Mounting Medium (Vector Laboratories). Tumors with FGFR1 protein expression higher than 50% were further analyzed on FGFR1 gene copy-numbers. Gene copy-numbers were assessed at 100x magnification using a Leica DM5500 B microscope system with Application Suite Advanced Fluorescence Software (Leica Microsystems). A minimum of 50 tumor cell nuclei were assessed on penicillin/streptomycin) and grown at 37°C and 5% CO 2 . All cell lines were routinely tested for Mycoplasma infection and were found negative.
Research. SDS, 2% β-mercaptoethanol, 0.02% bromophenol blue) was added and lysates were boiled for 10 minutes. The amount of protein in each sample was equalized using a BCA protein assay kit (Pierce).
Equal amounts of sample were subjected to SDS gel electrophoresis followed by western blotting.
Primary antibodies against HSP90 (sc-7947), p-ERK (sc-7383), ERK1 (sc-93), ERK2 (sc-154), and FGFR2 (sc-1884) were purchased from Santa Cruz. Antibodies against pFGFR (#3476), FGFR1 (#9740), p-AKT (#4060), and AKT (#2920) were from Cell Signaling. Secondary antibodies were obtained from Bio-Rad Laboratories. HSP90 expression was used as an internal standard to control for equal loading. AZD4547 and gefitinib were purchased from Selleckchem.
Colony formation assays
Cells were seeded in 6-well plates (20. 
CellTiter-Blue viability assay
Respectively 500 (BICR16) or 750 (SCC-147) cells per well were seeded in a 384-well plate. After 24 hours, drugs were added to the medium in 2-fold serial dilutions using a HP Direct Digital Dispenser.
After 5 days of culture CellTiter-Blue (Promega) was added. The conversion of resazurin into resorufin was measured by using an EnVision Multilabel Reader. Treatment with 10 μM phenyl arsenic oxideresulting in complete cell death -was used as a baseline for viability.
Combination indices were calculated using the Chou-Talalay method (27) . Cells were seeded in a 384-well plate and treated with 5*5 pairs of serially diluted drugs for 5 days (12.5nM-200nM gefitinib for SCC147, 25nM-400nM gefitinib for BICR16, and 0.125-2μM AZD4546 for both cell lines).
The indicated combination indices are the median combination indices of the 5*5 matrix.
Research. (Figure 1a, Supplementary Figure S1a, Supplementary Table S1 ). FGFR1 protein expression was unknown for one HPV-positive and six HPV-negative HNSCC, because all cores from these tumors were missing on TMA slides. Overexpression of FGFR1 protein was related to poor overall survival and poor disease-free survival in HPV-negative HNSCC (HR: 3.07; 95% CI: 1.74-6.90; P = 0.001, HR: 1.53; 95% CI: 1.04-2.39; P = 0.033) and remained significant in a multivariate model after bootstrapping (Figure 1b-c, Table 2, Supplementary Figure 1c- 
Sensitivity of FGFR-overexpressing HNSCC cell lines to AZD4547
Since we identified FGFR1 overexpression in HNSCC, we tested the sensitivity of six HNSCC cell lines to AZD4547 (Figure 2a) . Surprisingly, only CLL30 responded well to treatment. We next assessed the expression of FGFR1 and FGFR2 by western blotting (Figure 2b ). BICR16 and CCL30 were found to express FGFR1, whereas SCC147 expressed FGFR2. The overexpression was confirmed by IHC (Figure 2c) . The lack of FGFR expression in UTSCC9, -12A and -40 cell lines might explain the unresponsiveness to AZD4547.
We subsequently performed FISH analysis to investigate FGFR gene amplification as an underlying mechanism for high FGFR expression (Figure 2c) . We identified FGFR1 gene amplification in BICR16 and FGFR2 gene amplification in SCC147. The overexpression of FGFR1 in CCL30 cannot be explained by gene amplification and might be the result of post-transcriptional or post-translational regulation. To gain insights into the biochemical differences underlying sensitivity, we treated FGFRoverexpressing cells with AZD4547 and analyzed ERK and AKT activity (Figure 2d) . We observed complete inhibition of ERK in CCL30, but not in SCC147 or BICR16 cell lines.
Gefitinib confers sensitivity to AZD4547 treatment in resistant HNSCC cell lines
EGFR signalling is a known resistance mechanism to FGFR inhibition in multiple tumor types (29) . To assess the role of EGFR in AZD4547 resistance, we first determined EGFR expression in the FGFRoverexpressing HNSCC cell lines (Figure 3a) . Both AZD4547-resistant cell lines (BICR16 and (Figure 3b-c) . Combined treatment synergistically blocked growth in colony formation assays, indicating the involvement of EGFR signalling as a resistance mechanism to FGFR inhibition. We validated these results using a 5-day cell viability assay, in which cells were treated with increasing concentrations of both AZD4547 and gefitinib (Figure 3d-e) . To determine whether the combination treatment is synergistic, we calculated median combination indices across the different drug combinations. An index between 0.1 and 0.3 indicates strong synergism, between 0.3 and 0.7 is synergism, between 0.7 and 0.85 is moderate synergism, and a combination index close to 1 indicates an additive effect (30) . Using this analysis, we identified a synergistic interaction between AZD4547 and gefitinib in BICR16 cells (CI 0.46; SD 0.13) and a moderate synergistic interaction in SCC-147 cells (CI 0.76; SD 0.23).
Since AZD4547 did not affect MAPK/AKT signalling in resistant cell lines, we analysed these pathways upon co-treatment with gefitinib (Figure 3f) . Dual FGFR/EGFR inhibition completely reduced MAPK/AKT signalling, explaining the synergistic effect on growth inhibition.
DISCUSSION
In this study we report that high FGFR1 protein expression is a prognostic biomarker in HPV-negative HNSCC. Furthermore, the frequent overexpression of FGFR1 in HNSCC provides a rationale to test FGFR inhibitors in clinical trials. Here, we demonstrated that combined EGFR/FGFR inhibitor treatment can be used to treat FGFR inhibitor resistant HNSCC.
Our finding that 82% of HPV-positive and 75% of HPV-negative HNSCC overexpress FGFR1 is in concordance with previous reports, but it differs from a study by Freier et al. which reported high FGFR1 expression in only 12% of OSCC (5, 17, 31, 32) . In addition, we observed prognostic value for FGFR1 protein expression in HPV-negative HNSCC, which has not been reported by previous studies -although Hase et al. reported prognostic value for FGFR1 expression in oral cancer-associated fibroblast (32, 33) . These contradictions might be explained by differences in anti-FGFR1 antibodies to determine protein expression or study populations. Potential sources of selection bias should also be taken into account. The population in this study consists of only OSCC and OPSCC, and mainly advanced stage tumors, which is not representative for the HNSCC population. Therefore, the effect as stain intensity or the presence/absence of staining, compared to a cutoff value of 10% in our study (5, 17) . Our cutoff value has been optimized in the same population as in which the relationship with survival has been measured. This causes the measured effect to be overestimated. To correct for this, we internally validated the prognostic value of FGFR1 protein expression by bootstrapping on 5000
samples. The observed relationship should be externally validated in other HNSCC cohorts in future studies.
A small subset (3%) of HPV-negative HNSCC in this study showed amplification of the FGFR1 gene, which has previously been observed in HNSCC at varying rates (2-17%) (5-7,34,35) .
Interestingly, we only observed FGFR1 gene amplification in HPV-negative HNSCC, which was also found in large scale genomic studies. Whether this subgroup may respond to FGFR inhibitors should be investigated in HNSCC clinical trials, since FGFR1-amplified breast tumors responded well to dovitinib and lucitanib in clinical trials (20, 21) .
Previous preclinical models demonstrated the efficacy of FGFR inhibitors PD173074, BGJ398, RO4383596 and AZ8010 in HNSCC (16) (17) (18) (19) . Here we tested the activity of AZD4547 -a potent and selective pan-FGFR inhibitor currently in phase 2 clinical trial -in HNSCC cell lines. Only one out of six cell lines tested responded to AZD4547 mono-treatment. The unresponsiveness of three cell lines might be explained by a lack of FGFR1 or -2 overexpression. However, two cell lines displaying FGFR1 or -2 amplification were also unresponsive to AZD4547. We identified EGFR signalling as a resistance mechanism in both cell lines. Combined treatment of AZD4547 and the EGFR inhibitor gefitinib synergistically blocked growth and underlying MAPK/AKT signalling. Thus, FGFR1 is a potential therapeutic target in HNSCC and AZD4547/gefitinib combination therapy could be adopted to overcome EGFR mediated therapy resistance. The role of EGFR signalling as a resistance mechanism to FGFR inhibitor treatment has previously been reported in several tumor types, including HNSCC (19, 36) . Furthermore, combining radiotherapy with AZD4547 may be of interest for treating HNSCC, as previous studies report an increased sensitivity of prostate cancer and mesothelioma to radiotherapy when combined with FGFR1 inhibitors (37,38).
To conclude, we report FGFR1 as being frequently overexpressed in HNSCC and as a candidate prognostic biomarker in HPV-negative HNSCC. Our data furthermore provide a rationale for
Research. The HPV-positive and HPV-negative head and neck squamous cell carcinoma cohorts included patients who were treated in the University Medical Center Utrecht between 1996 and 2011. Clinical patient details and pathological tumor details were retrieved from electronic medical records and pathology reports. Nine head and neck squamous cell carcinoma patients were excluded from the study population because HPV-status was missing. HPV: human papillomavirus
Research. 138 Clinicopathological variables and follow-up data of 398 HPV-negative head and neck squamous cell carcinoma patients were retrieved from electronic medical records and are depicted in Table 1 . 24 HPV-negative HNSCC patients were excluded from survival analysis because they were treated with palliative intent. Expression of FGFR1 protein was determined by immunohistochemistry on tissue microarray slides containing tumor cores. 95% CI: 95% confidence interval, FGFR1: fibroblast growth factor receptor 1, HR: hazard ratio, NC: no confounder
